胰腺癌治疗的研究进展

剑 蒋(青海大学研究生院，中国)
大勇 谭(青海大学附属医院肝胆外科，中国)

摘要

胰腺癌（Pancreatic cancer，PC）是全球癌症死亡的主要原因，其全球负担在过去25年中增加了一倍多。胰腺癌发病率最高的地区包括北美、欧洲和澳大利亚，尽管这种增加在很大程度上是由于全球人口老龄化，但胰腺癌存在关键的可改变风险因素，如吸烟、肥胖、糖尿病和饮酒。这些风险因素的患病率在全球许多地区都在增加，导致胰腺癌的年龄调整发病率增加。尽管手术、化疗和放疗是治疗胰腺癌的主要方法，但由于其晚期发现和生物学特性，许多患者在接受治疗时效果不佳，导致生存率低。根据统计数据，胰腺癌的五年生存率通常低于10%。这意味着大多数患者在确诊后五年内无法存活。本研究旨在总结胰腺癌患者目前的治疗建议研究进展。

关键词

胰腺癌；治疗；研究进展

参考

Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: An update on diagnosis and management[J]. Aust J Gen Pract, 2019 Dec;48(12):826-831.

Jiang S, Fagman JB, Ma Y, et al. A comprehensive review of pancreatic cancer and its therapeutic challenges[J]. Aging (Albany NY), 2022,14(18):7635-7649.

Duan H, Li L, He S. Advances and Prospects in the Treatment of Pancreatic Cancer[J]. Int J Nanomedicine, 2023,18:3973-3988.

Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic Cancer: A Review of Current Treatment and Novel Therapies[J]. Invest Surg, 2023,31,36(1):2129884.

Song H, Jiang C. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma[J]. Expert Opin Drug Deliv, 2022,19(3):281-301.

Jiang S, Fagman JB, Ma Y, et al. A comprehensive review of pancreatic cancer and its therapeutic challenges[J]. Aging (Albany NY), 2022,14(18):7635-7649.

Mattiolo P, Kryklyva V, Brosens LA, et al. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic[J]. Expert Opin Ther Targets, 2022,26(1):1-4.

Xing L, Lv L, Ren J, Yu H, et al. Advances in targeted therapy for pancreatic cancer[J]. Biomed Pharmacother,2023,168:115717.

Liu X, Li Z, Wang Y. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer[J]. Adv Biol (Weinh), 2021,5(3):e1900236.

Hu ZI, O’Reilly EM. Therapeutic developments in pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2024,21(1):7-24.

Cao D, Song Q, Li J, et al. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer[J]. Expert Rev Mol Med, 2021,15,23:e21.

Yu Y, Zheng P, Chen Y, et al. Advances and challenges of neoadjuvant therapy in pancreatic cancer[J]. Asia Pac J Clin Oncol, 2021,17(6):425-434.

Brown TJ, Reiss KA, O’Hara MH. Advancements in Systemic Therapy for Pancreatic Cancer[J]. Am Soc Clin Oncol Educ Book, 2023,43:e397082.

Jaidev LR, Chede LS, Kandikattu HK. Theranostic Nanoparticles for Pancreatic Cancer Treatment[J]. Endocr Metab Immune Disord Drug Targets, 2021,21(2):203-214.

Andersson R, Haglund C, Seppänen H, et al. Pancreatic cancer - the past, the present, and the future[J]. Scand J Gastroenterol, 2022,57(10):1169-1177.

Sharma N, Arora V. Strategies for drug targeting in pancreatic cancer[J]. Pancreatology, 2022,22(7):937-950.

Deiana C, Agostini M, Brandi G, et al. The trend toward more target therapy in pancreatic ductal adenocarcinoma[J]. Expert Rev Anticancer Ther, 2024,24(7):525-565.

Trunk A, Miotke L, Nevala-Plagemann C, et al. Emerging Treatment Strategies in Pancreatic Cancer[J]. Pancreas, 2021,50(6):773-787.

Ruff SM, Pawlik TM. Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review[J]. Front Biosci (Landmark Ed), 2024,13(3):101.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i10.21674